Myriad to Announce Fiscal Second-Quarter 2016 Financial Results on February 2
January 21 2016 - 4:05PM
Myriad Genetics, Inc. (NASDAQ:MYGN) today announced that it will
hold its fiscal second-quarter 2016 sales and earnings conference
call with investors and analysts at 4:30 p.m. ET on Tuesday, Feb.
2. During the call, Mark C. Capone, president and CEO and
Bryan Riggsbee, chief financial officer, will provide an overview
of Myriad’s financial performance for the fiscal second-quarter and
provide a business update.
To listen to the call, interested parties in the United States
may dial 800-676-1873 or +1 303-223-4378 for international
callers. All callers will be asked to reference reservation
number 21802448. The conference call also will be available through
a live webcast and a slide presentation pertaining to the earnings
call will also be available under the investor section of our
website at www.myriad.com. A replay of the call will be
available two hours after the end of the call for seven days and
may be accessed by dialing 800-633-8284 within the United States or
+1 402-977-9140 for international callers and entering reservation
number 21802448.
About Myriad Genetics
Myriad Genetics Inc., is a leading personalized medicine company
dedicated to being a trusted advisor transforming patient lives
worldwide with pioneering molecular diagnostics. Myriad
discovers and commercializes molecular diagnostic tests that;
determine the risk of developing disease, accurately diagnose
disease, assess the risk of disease progression, and guide
treatment decisions across six major medical specialties where high
value diagnostics can significantly improve patient care and lower
healthcare costs. Myriad is focused on three strategic
imperatives: transitioning and expanding its hereditary
cancer markets, diversifying its product portfolio through the
introduction of new products and increasing its international
contribution. For more information on how Myriad is making a
difference, please visit the Company's website: www.myriad.com.
Myriad, the Myriad logo, BART, BRACAnalysis, Colaris, Colaris
AP, myPath, myRisk, myRisk Hereditary Cancer, myChoice, myPlan,
BRACAnalysis CDx, Tumor BRACAnalysis CDx, myChoice HRD, Vectra and
Prolaris are trademarks or registered trademarks of Myriad
Genetics, Inc. or its wholly owned subsidiaries in the United
States and foreign countries. MYGN-F, MYGN-G
Media Contact: Ron Rogers
(801) 584-3065
rrogers@myriad.com
Investor Contact: Scott Gleason
(801) 584-1143
sgleason@myriad.com
Myriad Genetics (NASDAQ:MYGN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Myriad Genetics (NASDAQ:MYGN)
Historical Stock Chart
From Sep 2023 to Sep 2024